This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2017 Jun 8;376(23):2300-2302.

doi: 10.1056/NEJMc1701990.

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor

Michael Fralick¹, Sebastian Schneeweiss¹, Elisabetta Patorno¹

Affiliations

PMID: 28591538
DOI: 10.1056/NEJMc1701990

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor

Michael Fralick et al. N Engl J Med. 2017.

. 2017 Jun 8;376(23):2300-2302.

doi: 10.1056/NEJMc1701990.

Authors

Michael Fralick¹, Sebastian Schneeweiss¹, Elisabetta Patorno¹

Affiliation

¹ Brigham and Women's Hospital, Boston, MA mif823@mail.harvard.edu.

PMID: 28591538
DOI: 10.1056/NEJMc1701990

No abstract available

PubMed Disclaimer

Comment in

Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?
Patoulias D, Papadopoulos C, Doumas M. Patoulias D, et al. Endocrinol Diabetes Nutr (Engl Ed). 2022 Aug-Sep;69(7):547-549. doi: 10.1016/j.endien.2022.06.011. Endocrinol Diabetes Nutr (Engl Ed). 2022. PMID: 36084991 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information